1. Role of the DEK oncogene in the development of squamous cell carcinoma

   • Kazuhisa Ishida
   • Takayuki Nakashima
   • Hiroyuki Tomita

   Review Article Open access 12 July 2020 Pages: 1563 - 1569

2. Neo-adjuvant chemotherapy alone for the locally advanced rectal cancer: a systematic review

   • Dimitrios K . Manatakis
   • Nikolaos Gouvas
   • Evangelos Xynos

   Review Article 14 July 2020 Pages: 1570 - 1580

   

3. Evaluation of COVID 19 infection in 279 cancer patients treated during a 90-day period in 2020 pandemic

   • Mozaffar Aznab

   Original Article 11 July 2020 Pages: 1581 - 1586

4. Association between chronic kidney disease and mortality in stage IV cancer

   • Taisuke Ishii
   • Takuya Fujimaru
   • Yasuhiro Komatsu

   Original Article 08 June 2020 Pages: 1587 - 1595

   

5. Chemoradiotherapy for high-risk stage II laryngeal cancer

   • Satoshi Hamauchi
   • Tomoya Yokota
   • Hirofumi Yasui

   Original Article 22 May 2020 Pages: 1596 - 1603

   

6. Usefulness of fluorescence visualization-guided surgery for early-stage tongue squamous cell carcinoma compared to iodine vital staining

   • Yusuke Ikeda
   • Taiki Suzuki
   • Takeshi Nomura

   Original Article Open access 25 May 2020 Pages: 1604 - 1611

   

7. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma

   • Fengrui Zhou
   • Xin Wang
   • Yan Yu

   Original Article 19 May 2020 Pages: 1612 - 1623

   

8. The efficacy and toxicity of metronomic oral vinorelbine monotherapy in patients with non-small cell lung cancer: a meta-analysis

   • Ke Xu
   • Tao Liu
   • Tao Ren

   Original Article 29 May 2020 Pages: 1624 - 1634

   

9. Comparison of S-1–cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105) trials

   • Hisato Kawakami
   • Kazumasa Fujitani
   • for the Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)

   Original Article 03 June 2020 Pages: 1635 - 1643

   

10. Risk factors for metachronous colorectal cancer in Lynch syndrome patients: a registry-based observational mono-institutional study cohort

    • Stefano Signoroni
    • Guglielmo Niccolò Piozzi
    • Marco Vitellaro

    Original Article 19 May 2020 Pages: 1644 - 1652

    

11. Signet ring cell component in pretreatment biopsy predicts pathological response to preoperative chemoradiotherapy in rectal cancer

    • Xue Chao
    • Zixian Wang
    • Jingping Yun

    Original Article 16 June 2020 Pages: 1653 - 1662

    

12. Novel classification of ovarian metastases originating from colorectal cancer by radiological imaging and macroscopic appearance

    • Mayumi Kobayashi Kato
    • Dai Shida
    • Tomoyasu Kato

    Original Article 03 June 2020 Pages: 1663 - 1671

    

13. Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients

    • Warit Ruanglertboon
    • Michael J. Sorich
    • Ashley M. Hopkins

    Original Article 16 May 2020 Pages: 1672 - 1677

    

14. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab

    • Kotaro Suzuki
    • Tomoaki Terakawa
    • Masato Fujisawa

    Original Article 02 June 2020 Pages: 1678 - 1686

    

15. Impact of centralization in primary retroperitoneal sarcoma treatment: analysis using hospital-based cancer registry data in Japan

    • Tomokazu Kimura
    • Koji Kawai
    • Hiroyuki Nishiyama

    Original Article 25 May 2020 Pages: 1687 - 1694

    

16. Blood platelet volume predicts treatment-specific outcomes of metastatic castration-resistant prostate cancer

    • Wataru Fukuokaya
    • Takahiro Kimura
    • Shin Egawa

    Original Article 02 June 2020 Pages: 1695 - 1703

    

17. Predicting factors for progression to castration resistance prostate cancer after biochemical recurrence in patients with clinically localized prostate cancer who underwent radical prostatectomy

    • Takeshi Hashimoto
    • Jun Nakashima
    • Yoshio Ohno

    Original Article 04 June 2020 Pages: 1704 - 1710

    

18. Predictive factors of rectal hemorrhage in patients with localized prostate cancer who underwent low-dose-rate brachytherapy

    • Tomoki Taniguchi
    • Koji Iinuma
    • Takuya Koie

    Original Article 05 June 2020 Pages: 1711 - 1717

    

19. Suppressive effect upon carboplatin hypersensitivity reaction via pegylated liposomal doxorubicin combination therapy

    • Kyoko Shimada
    • Shoji Nagao
    • Satoshi Yamaguchi

    Original Article 23 May 2020 Pages: 1718 - 1725

    

20. Aggressive surgery for advanced ovarian cancer decreases the risk of intraperitoneal recurrence

    • Shinichi Tate
    • Kyoko Nishikimi
    • Makio Shozu

    Original Article 04 June 2020 Pages: 1726 - 1735

    

21. Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma

    • Hideki Goto
    • Shinichi Makita
    • Takanori Teshima

    Original Article Open access 24 May 2020 Pages: 1736 - 1743

    

22. Correction to: Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)

    • Tomoro Hishiki
    • Kimikazu Matsumoto
    • For the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)

    Correction 04 August 2020 Pages: 1744 - 1745